DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Clinical trials for DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT trials appear
Sign up with your email to follow new studies for DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug cocktail targets tough brain cancers in kids
Disease control Recruiting nowThis study tests two drug combinations given after radiation for children and young adults with aggressive brain tumors (high-grade glioma or DIPG). One group receives ribociclib plus everolimus; another gets ribociclib plus temozolomide. The goal is to see if these combinations …
Matched conditions: DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated May 17, 2026 00:47 UTC
-
New drug duo takes on deadly brain cancer in early trial
Disease control Recruiting nowThis trial tests two drugs, avutometinib and defactinib, alone or with a third drug (temozolomide), in people with aggressive brain tumors like glioblastoma. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 182 adults with recurrent …
Matched conditions: DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated May 17, 2026 00:45 UTC
-
Targeted radiation shows promise for aggressive brain tumors in early trial
Disease control Recruiting nowThis study tests a new radioactive drug, 177Lu-PSMA-617, to see if it is safe for people with a fast-growing type of brain tumor called IDH wild type glioma. The drug targets a protein (PSMA) found on these tumor cells and delivers radiation directly to them. About 20 adults whos…
Matched conditions: DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC